Skip to Content
Merck
All Photos(1)

Documents

450960

Sigma-Aldrich

Lutetium(III) chloride

anhydrous, powder, 99.99% trace metals basis

Synonym(s):

Lutetium chloride, Lutetium trichloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
LuCl3
CAS Number:
10099-66-8
Molecular Weight:
281.33
EC Number:
233-240-1
MDL number:
MFCD00011099
UNSPSC Code:
12352302
PubChem Substance ID:
24868595
NACRES:
NA.23

grade

anhydrous

Assay

99.99% trace metals basis

form

powder

reaction suitability

reagent type: catalyst
core: lutetium

impurities

≤150.0 ppm Trace Rare Earth Analysis

mp

905 °C (lit.)

density

3.98 g/mL at 25 °C (lit.)

SMILES string

Cl[Lu](Cl)Cl

InChI

1S/3ClH.Lu/h3*1H;/q;;;+3/p-3

InChI key

AEDROEGYZIARPU-UHFFFAOYSA-K

Related Categories

Application

Lutetium(III) chloride can be used:
  • As a precursor to synthesize chiral bridged lutetium catalyst for asymmetric hydroamination.
  • As a starting material to prepare doped lutetium oxide nanophosphors.
  • To fabricate scintillation detectors such as lutetium aluminum garnet (LuAG).

accessory

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Development of new technologies for the manufacturing of nanocrystalline scintillation materials
Nikoloz V Jalabadze, et al.
IEEE transactions on nuclear science, 55, 1514-1522 (2008)
A Chiral-Bridged Aminotroponiminate Complex of Lutetium as Catalyst for the Asymmetric Hydroamination
Nils Meyer, et al.
Organometallics, 25, 4179-4182 (2006)
Swayamjeet Satapathy et al.
Clinical nuclear medicine, 45(9), e393-e399 (2020-07-01)
Advanced inoperable/metastatic neuroendocrine tumors (NETs) pose a therapeutic challenge with limited treatment options. Peptide receptor radionuclide therapy (PRRT), being specific in targeting the somatostatin receptors, is a promising and viable option in this setting. In this study, we intended to
Swayamjeet Satapathy et al.
Nuclear medicine communications, 41(7), 629-635 (2020-05-07)
Peptide receptor radionuclide therapy (PRRT) has been shown to be useful in inoperable/metastatic medullary thyroid carcinoma (MTC). However, the role of concomitant PRRT and low-dose capecitabine therapy has not yet been studied in these patients. This study was conducted to
Sanjay Kumar Saxena et al.
Cancer biotherapy & radiopharmaceuticals, 32(10), 364-370 (2017-12-22)
The primary objective of this investigation is the development of a strategy for the synthesis of polyhydroxamic acid (PHA)-grafted cellulose film, its characterization, and evaluation of its usefulness for the preparation of
View All Related Papers

Articles

Rare Earth Crisis—Supply/Demand Situation 2010–2015

Rare earth elements are vital in everyday life worldwide: catalysts in cars, colors in screens, magnets in electronics. Essential for modern living.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service